A Prospective Observational Multi-institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid Leukemia (MISFIC Study): A Real World Scenario from India

[1]  Jung‐Chung Lin,et al.  Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials , 2018, Antimicrobial Agents and Chemotherapy.

[2]  O. Dekkers,et al.  The burden of Invasive Aspergillosis in patients with haematological malignancy: A meta-analysis and systematic review. , 2018, The Journal of infection.

[3]  M. Tormo,et al.  Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high‐risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real‐world comparison , 2018, Mycoses.

[4]  F. Şahin,et al.  Epidemiology and analysis of invasive fungal infections in patients withhematological malignancies: a single-center real-life experience , 2017, Turkish journal of medical sciences.

[5]  B. George,et al.  Invasive fungal infection following chemotherapy for acute myeloid leukaemia—Experience from a developing country , 2017, Mycoses.

[6]  L. Pagano,et al.  ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients , 2016, Haematologica.

[7]  K. Cederlund,et al.  Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes , 2015, European journal of haematology.

[8]  Yoo-Jin Kim,et al.  Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single‐centre retrospective study in Korea and clinical considerations , 2015, Mycoses.

[9]  B. Ko,et al.  High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan , 2015, PloS one.

[10]  T. Tan,et al.  Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  V. Pavone,et al.  Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) , 2015, Haematologica.

[12]  J. Meis,et al.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  R. Foà,et al.  Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. , 2014, Leukemia research.

[14]  A. Chakrabarti,et al.  Empirical Amphotericin B therapy on Day 4 or Day 8 of Febrile Neutropenia , 2014, Mycoses.

[15]  D. Kontoyiannis,et al.  Incidence Density of Invasive Fungal Infections during Primary Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Patients in a Tertiary Cancer Center, 2009 to 2011 , 2013, Antimicrobial Agents and Chemotherapy.

[16]  A. Chakrabarti,et al.  Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies , 2013, Mycoses.

[17]  John W. Wilson,et al.  The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole , 2013, American journal of hematology.

[18]  Tim Spelman,et al.  Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period , 2012, Haematologica.

[19]  P. Vanhems,et al.  Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[20]  K. Sepkowitz,et al.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  H. Einsele,et al.  Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies , 2008, International journal of hematology.

[22]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  B. Thiers.  Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia , 2008 .

[24]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.